Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments
| Autor: | Akinori Sugitani, Satoru Katayama, Takanori Sako, Hisashi Suyama, Kazuhiro Kato, Yuji Kawasaki, Mistunobu Yamamoto, Kazuhito Yasuda, Tadashi Igishi, Yasushi Shigeoka, Eiji Shimizu, Shingo Matsumoto, Yutaka Hitsuda |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Paclitaxel Phases of clinical research chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine medicine Carcinoma Humans Treatment Failure Lung cancer Survival analysis Aged business.industry Respiratory disease General Medicine Middle Aged medicine.disease Antineoplastic Agents Phytogenic Survival Analysis respiratory tract diseases Surgery Clinical trial Treatment Outcome chemistry Female Non small cell business |
| Zdroj: | Oncology. 66:347-352 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000079481 |
| Popis: | Objective: New effective therapy is desirable for patients with non-small cell lung cancer (NSCLC) who have failed previous treatments. Fractionated administration of paclitaxel may be less toxic and more active against NSCLC. The aim of this study was to evaluate the activity and toxicity of weekly paclitaxel therapy for NSCLC in a second-line setting. Methods: Patients with pathological or cytological diagnosis of NSCLC, measurable lesions, and one or more prior therapies were enrolled. We administered weekly infusions of 80 mg/m2 paclitaxel 3 times in a 4-week cycle. In the absence of progressive disease or intolerable toxicity, each patient was treated for a minimum of 4 cycles. Results: Of 39 patients enrolled, 1 patient achieved complete response and 11 patients achieved partial response (response rate, 31%: 95% confidence interval, 17–48%). The median survival time was 43 weeks (range, 7–128 weeks). Grade 3 or 4 leukopenia occurred in only 7 patients (18%). Neurotoxicity was the most frequent adverse effect (grades 1 and 2.26 and 5%, respectively). Although all patients recovered rapidly with corticosteroid treatment, drug-induced pneumonitis was observed in 3 patients (8%). Conclusion: Low-dose weekly paclitaxel is a promising therapy with high effectiveness for advanced NSCLC in patients with NSCLC who have failed previous treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|